Cronos Group Inc.

CRON Healthcare Drug Manufacturers Specialty & Generic

Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024. In the quarter to June 2026, revenue grew 58.4%, EPS grew 190.0%, free cash flow grew 2,279.2% and total debt fell 4.71%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

3.22 0.02 +0.63%
Market cap
$1.2B
P/E
16.1×
Fwd P/E
32.2×
Dividend yield
—
F-score
5/9
Altman Z
12.67
Beneish M
−2.05
Dividend safety
20/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

27.80 0.00 251.00 13.90
P/S ratio
8.05 6.88 5.97 5.80
P/FCF ratio
0.00 0.00 36.36 21.01
P/Operating CF
80.02 85.22 87.38 43.26
P/B ratio
0.94 0.88 0.85 0.93
EV/Sales
1.83 1.21 0.82 1.36
EV/EBITDA
0.00 0.00 198.71 19.33
EV/FCF
(42.17) (936.49) 5.02 4.91
Current Ratio
22.45 19.59 21.87 16.18
Net Debt/EBITDA
(271.71) 264.61 (433.32) (73.84)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
3.60% (0.38%) 0.40% 7.19%
Free Cash Flow Yield
(0.54%) (0.02%) 2.75% 4.76%
Free Cash Flow per Share
0.02 0.02 0.02 0.06
Book value per Share
2.96 2.98 2.96 2.99
Free Cash Flow
8.72 9.56 8.93 22.23
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates